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Abstract
Background: The COMT Val158Met polymorphism modulates cortical dopaminergic catabolism, and predicts individual
differences in prefrontal executive functioning in healthy adults and schizophrenic patients, and associates with EEG
differences during sleep loss. We assessed whether the COMT Val158Met polymorphism was a novel marker in healthy
adults of differential vulnerability to chronic partial sleep deprivation (PSD), a condition distinct from total sleep loss and
one experienced by millions on a daily and persistent basis.
Methodology/Principal Findings: 20 Met/Met,6 4Val/Met, and 45 Val/Val subjects participated in a protocol of two baseline
10h time in bed (TIB) nights followed by five consecutive 4 h TIB nights. Met/Met subjects showed differentially steeper
declines in non-REM EEG slow-wave energy (SWE)—the putative homeostatic marker of sleep drive—during PSD, despite
comparable baseline SWE declines. Val/Val subjects showed differentially smaller increases in slow-wave sleep and smaller
reductions in stage 2 sleep during PSD, and had more stage 1 sleep across nights and a shorter baseline REM sleep latency.
The genotypes, however, did not differ in performance across various executive function and cognitive tasks and showed
comparable increases in subjective and physiological sleepiness in response to chronic sleep loss. Met/Met genotypic and
Met allelic frequencies were higher in whites than African Americans.
Conclusions/Significance: The COMT Val158Met polymorphism may be a genetic biomarker for predicting individual
differences in sleep physiology—but not in cognitive and executive functioning—resulting from sleep loss in a healthy,
racially-diverse adult population of men and women. Beyond healthy sleepers, our results may also provide insight for
predicting sleep loss responses in patients with schizophrenia and other psychiatric disorders, since these groups
repeatedly experience chronically-curtailed sleep and demonstrate COMT-related treatment responses and risk factors for
symptom exacerbation.
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Introduction
The catechol-O-methyltransferase (COMT) valine158methionine
(Val158Met) polymorphism, replaces valine (Val) with methionine
(Met) at codon 158 of the COMT protein. As a result of this
common substitution, activity of the COMT enzyme, which
modulates dopaminergic catabolism in the prefrontal cortex
(PFC), is reduced 3-to-4-fold in COMT Met carriers compared
with Val carriers, translating into more dopamine availability at
the receptors and higher cortical dopamine concentrations [1].
This COMT polymorphism functionally predicts less efficient PFC
functioning and poor working memory performance on some tasks
in healthy subjects [2–5] and in patients with schizophrenia [1–
4,6] (but see [7]), carrying the high-activity Val allele.
In healthy men, the COMT Val158Met polymorphism has been
associated with sleep physiology. In acute total sleep deprivation
(TSD), in which an entire night of sleep is lost, the polymorphism
predicted interindividual differences in brain alpha oscillations in
wakefulness and 11–13 Hz EEG activity in wakefulness, rapid-eye
movement (REM) and non-REM sleep [8]. It also modulated the
effects of the wake-promoting drug modafinil on subjective well-
being, sustained vigilant attention and executive functioning, and
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was not associated with subjective sleepiness, slow-wave activity or
slow-wave sleep changes in recovery sleep following TSD or at
baseline [9,10].
In sleep and neurodegenerative disorders, the COMT Val158-
Met polymorphism also has been linked to daytime sleepiness.
Val/Val female patients with narcolepsy fell asleep two times faster
than the Val/Met or Met/Met genotypes during the Multiple Sleep
Latency Test (MSLT) while the opposite was true for males [11].
In addition, Met/Met patients with narcolepsy showed more sleep
onset REM periods during the MSLT while Val/Val subjects
showed less sleep paralysis [11] and were more responsive to
modafinil’s stimulating effects [12]. Met/Met and Val/Met patients
with Parkinson’s disease demonstrated higher subjective daytime
sleepiness than Val/Val subjects [13], although a larger study failed
to confirm this finding [14].
Beyond its relationship to sleep and to cognitive function, the
COMT Val158Met polymorphism has been linked to psychiatric
conditions. This polymorphism has been associated with suscep-
tibility to schizophrenia [1,15] and bipolar disorder [16–18] and
also has been associated with other mood disorders including
major depressive disorder, obsessive compulsive disorder, eating
disorders and panic and anxiety disorders [1,19,20]. Importantly,
this COMT polymorphism predicted behaviors in healthy adults
which tie to psychiatric disorders [2,3]—thus, investigation of this
genotype in healthy individuals has applications for clinical
research.
Considering the aforementioned literature, we hypothesized
that COMT would be a novel genetic biomarker in healthy adult
sleepers of differential vulnerability to sleep homeostatic, sleepiness
and neurobehavioral responses during chronic PSD. Chronic PSD
is a condition representative of real world situations, experienced
by millions on a consecutive and persistent basis, and associated
with serious health consequences [21]. In addition, chronic PSD is
similar to the sleep-wake patterns found in schizophrenia—and in
bipolar disorder and other mood disorders—whereby patients
experience repeatedly curtailed or fragmented sleep rather than
lose an entire night of sleep [22]. Thus, as an ancillary objective,
we investigated responses to such PSD conditions in healthy adults
as a putative experimental model for predicting sleep, alertness
and cognitive responses to sleep loss in patients with psychiatric
disorders.
Materials and Methods
Ethics Statement
The protocols described below were approved by the Institu-
tional Review Board of the University of Pennsylvania. After
complete description of the study, and prior to study entry, written
informed consent was obtained from all subjects according to the
principles expressed in the Declaration of Helsinki; all subjects
received compensation for participation.
Participants
One hundred and twenty-nine subjects participated in one of
two chronic PSD experiments (described below). Following
protocol completion, subjects were genotyped for the COMT
Val158Met polymorphism. This was a retrospective analysis; thus,
COMT genotypes were not matched. The COMT Val158Met
genotypic and allelic frequencies for whites and African Americans
(Table 1) approximated those reported in other studies using
mixed ethnicity samples [23].
Subjects met the following inclusionary criteria, as detailed in
[24]: age between 22–45 yrs.; physically and psychologically
healthy, as assessed by physical examination and history; no
clinically significant blood chemistry abnormalities; drug-free
urine samples; good habitual sleep, between 6.5–8.5 h daily
duration with regular bedtimes, and wake-up times between 0600–
0900 h (verified by sleep logs and wrist actigraphy for $one week
before study entry); absence of extreme morningness/eveningness;
absence of sleep or circadian disorders, assessed by questionnaire
and polysomnography; absence of psychiatric illness or adverse
neuropsychiatric reaction to sleep deprivation; no alcohol or drug
abuse history; no current use of medical or drug treatments
(excluding oral contraceptives).
Experimental Design
Subjects participated in an 11- or 16-day experiment in the
Sleep and Chronobiology Laboratory at the Hospital of the
University of Pennsylvania. Only data from the first seven nights of
the protocols—which were procedurally identical—were analyzed.
On the two baseline nights, subjects received 10 h time in bed
(TIB) from 2200–0800 h to reduce any pre-existing sleep debt; on
the subsequent five nights, subjects received 4 h TIB (0400–
0800 h).
During the protocol, laboratory conditions and scheduled
activities were highly controlled. Ambient light remained at ,50
lux during wakefulness, and at ,1 lux (darkness) during sleep.
Temperature was maintained at 2261uC. Subjects were contin-
uously monitored by trained staff. Between performance bouts,
they were restricted from strenuous activities or having visitors, but
could read, play games, watch movies, and interact with staff to
help remain awake. Subjects received three standardized meals per
day and an optional evening snack. Caffeine, turkey, bananas,
alcohol and tobacco were prohibited.
Neurobehavioral Assessments
Subjects performed a computerized neurobehavioral test
battery every 2 h during wakefulness, as detailed in [24], which
included: the Karolinska Sleepiness Scale (KSS), a Likert-type
subjective sleepiness scale; a visual analog scale of fatigue (VAS)
anchored by ‘‘fresh as a daisy’’ and ‘‘tired to death’’; the Profile of
Mood States (POMS), a scale assessing transient affective states;
the Digit Symbol Substitution Task (DSST), a cognitive through-
put task; the Digit Span (DS) task, a working memory storage
capacity test, given in forward and backward versions and
summed as a total number correct measure; and the Psychomotor
Vigilance Task (PVT), a sustained attention test utilizing reaction
times as a behavioral alertness assay. Subjects remained seated
throughout testing, were behaviorally monitored, and were
instructed to perform to the best of their ability and use
compensatory effort to maintain performance. Baseline values
were derived from the second baseline day (B2). Daily values for
each performance task were calculated by averaging scores from
all test bouts that day.
Other Measurements
Before the study, subjects completed questionnaires on
demographic, clinical sleepiness, sleep–wake and circadian-related
variables, and psychosocial/personality traits, as detailed in [24],
including the Epworth Sleepiness Scale, the Morningness-Even-
ingness Composite Scale, the Beck Depression Inventory, the
Eysenck Personality Inventory and the North American Adult
Reading Test. At partial sleep deprivation/restriction night 5
(SR5), four standardized executive function tests were adminis-
tered: the Hayling and Brixton tests, the Controlled Oral Word
Association Test, and the Tower of London. In the 11-day
protocol, a modified Maintenance of Wakefulness Test (MWT)
COMT Predicts Differences in Sleep Physiology
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administered at B2 and SR5 (a single trial was conducted between
1430–1600 h) using a standard recording montage. Before each
trial, the lights were dimmed to ,10 lux and subjects were
instructed to ‘‘keep your eyes open and try not to fall asleep’’. Each
trial was terminated at the first microsleep (10 seconds of theta
activity) [25] determined by the C3/A2 derivation or at 30
minutes if sleep onset did not occur. MWT scores represented
either the time (minutes) to microsleep initiation or 30 minutes (if
no microsleep occurred).
Sleep Architecture
Polysomnography. The polysomnographic (PSG) montage
included frontal (Fz), central (C3), and occipital (O2) EEG,
bilateral EOG, submental EMG, and ECG. Data were recorded
from 2200–0800 h on B2, and from 0400–0800 h on partial sleep
deprivation/restriction night 1 (SR1) and SR5. Records were
visually scored in 30-second epochs using standard scoring criteria
by a trained scorer blind to COMT typing.
EEG Analysis. After visually determined artifact rejection,
the EEG was sampled at 128 Hz and spectral analysis of 3 sleep
EEG derivations (C3/A2; Fz/A1; O2/A1) was performed with
Fast Fourier Transform averaged across consecutive 30-second
epochs (average of 6 5-second epochs, resulting in a frequency
resolution of 0.2 Hz). We chose to examine the C3, Fz and O2
derivations, since we have found differential genotype changes in
these derivations in prior studies [24]. For each night, slow-wave
energy (SWE) in the delta band (0.5–4.5 Hz) was totaled over all
epochs of non-REM (visually-scored stages 2–4) sleep. Power in
the delta band (SWA) was calculated by dividing SWE by the
number of non-REM sleep epochs. For B2, absolute values were
determined for each hour of sleep for SWE and SWA; for SR1 and
SR5, SWE and SWA were normalized by calculating the percent
of the corresponding B2 hour. For some records, EEG signal
quality was insufficient or contained too much artifact for reliable
power spectral analysis (Figures 1 and 2). Although the delta band
was of primary interest, we also examined other frequency bands
in both non-REM and REM sleep which were defined as follows:
theta (4.5–8 Hz), alpha (8–12 Hz), sigma (12–14 Hz), and beta
(14–30 Hz).
Genotyping
Genomic DNA was extracted from whole blood using Qiagen’s
QIAamp DNA Blood Mini Kit (Catalog #51106). COMT
genotypes were determined by PCR-RFLP analysis. A G-to-A
substitution at codon 158 encoding valine or methionine generates
this polymorphism. The target sequence was PCR-amplified and
the product was digested by the restriction enzyme Nla III and
electrophoresed in an 8% polyacrylamide gel to detect the two
alleles, as described in [26].
Statistical Analyses
Mixed model analyses of covariance (ANCOVA), with day or
hour as the within-subjects (repeated measures) factor, genotype as
the between-group factor, and ethnicity as a covariate, were used
to analyze MWT, PSG, EEG, PVT, KSS, VAS, POMS, DSST
and DS data. Greenhouse–Geisser corrections were applied to all
within-subjects effects. One-way ANCOVA, with ethnicity as a
covariate, were used to analyze demographic and pre-study
measures, PSG, MWT and cognitive, executive function and sleep
Table 1. Characteristics of Met/Met, Val/Met and Val/Val Subjects (Mean 6 SD).
Characteristic Met/Met Val/Met Val/Val p*
N( % ) 20 (15.5%) 64 (49.6%) 45 (34.9%)
Age 29.766.9 29.966.7 30.267.3 0.969
BMI (kg/m
2) 24.9863.91 24.9163.05 24.1963.90 0.248
Sex (M/F) 7/13 35/29 24/21 0.277
Ethnicity (White/African American/Other)
# 14(.29)/6(.08)/0(.00) 23(.47)/39(.51)/2(.50) 12(.24)/31(.41)/2(.50)
Morningness-Eveningness Composite Scale 39.3565.91 39.8666.06 40.1965.04
a 0.978
Epworth Sleepiness Scale 4.4562.86 4.9563.08 4.8663.16
b 0.902
Beck Depression Inventory (BDI) 1.4762.29
c 1.2761.77
d 1.8262.77 0.485
Eysenck Personality Inventory (Extraversion subscale) 15.1164.45
c 15.0863.93
e 15.8863.44
a 0.377
North American Adult Reading Test (IQ) 109.0868.34 107.1467.13
f 102.7968.45
{g 0.028
Sleep Onset by Actigraphy** 23:5061.20 h 24:0060.88 h
d 23:4460.80 h
b 0.363
Sleep Offset by Actigraphy** 08:0261.27 h 07:5460.92 h
d 07:4660.85 h
b 0.748
Sleep Midpoint by Actigraphy** 04:0660.33 h 03:5760.32 h
d 04:0160.37 h
b 0.448
Total Sleep Time** (Sleep Duration) 8.2160.70 h 7.9460.70 h
d 8.0360.74 h
b 0.592
an=42.
bn=44.
cn=19.
dn=63.
en=62.
fn=61.
gn=43.
{Lower than Met/Met and Val/Met,p ,0.05, Bonferroni correction.
*p values are for the comparison of the three genotypes.
**One week prior to study entry.
#Genotypic frequencies are in parentheses. Met allele frequency was .520 for whites and .340 African Americans; Val allele frequency was .480 for whites and .660
African Americans. The ethnicities showed Met/Met genotypic (x
2=9.48, p=0.002) and allelic differences (x
2=8.43, p=0.004).
doi:10.1371/journal.pone.0029283.t001
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gender was investigated as an additional factor because of previous
findings [11]; however, no significant gender differences were
found. Post-hoc comparisons using Bonferroni-adjusted probabil-
ities examined significant group differences for all measures. SPSS
version 15.0 (SPSS Inc., Chicago, IL) was used for statistical
analyses; p#0.05 was considered significant.
Results
Demographic and Pre-study Variables
There were Met/Met genotypic differences (x
2=9.48, p=0.002)
and Met allelic differences (x
2=8.43, p=0.004) between whites
and African Americans (Table 1); therefore, ethnicity was
statistically controlled for as a covariate in all analyses. Met/Met
and Val/Met individuals had higher IQ scores than Val/Val
subjects (Table 1), although the groups did not differ significantly
in other demographic variables including age, body mass index, or
sex. Moreover, the groups did not show differences in psychoso-
cial/personality traits, pre-study sleep variables, clinical sleepiness
or circadian phase markers (Morningness-Eveningness chronotype
and sleep midpoint).
Sleep Physiology
Non-REM EEG Slow-Wave Energy and Slow-Wave
Activity. Across B2, the genotypes did not differ in SWE or
SWA calculated from the C3 (Figure 1A, 1B; SWE: F2,88=1.12,
p=0.332; SWA: F2,88=0.55, p=0.577), Fz (Figure 1C, 1D; SWE:
Figure 1. Hourly slow-wave energy (SWE) and slow-wave activity (SWA) during baseline for the COMT Val158Met genotypes. Mean
(6SEM) hourly SWE and SWA derived from the C3 (A, B), Fz (C, D) or O2 (E, F) channels during baseline for Met/Met (open circles), Val/Met (gray
triangles) and Val/Val (closed circles) subjects. As expected, SWE and SWA showed a typical pattern of dissipation across the baseline night in all 3
channels in all genotypes (denoted by *, p,0.0001), but did not show a differential pattern of decline across genotypes. The groups also did not
show significant differences in SWE or SWA derived from the C3, Fz or O2 channels. In some records, EEG signal quality was insufficient or contained
too much artifact for reliable power spectral analysis. Thus, the final sample sizes were as follows: for C3, Met/Met (n=19), Val/Met (n=60), and Val/Val
(n=39) subjects; for Fz, Met/Met (n=18), Val/Met (n=62), and Val/Val (n=42) subjects; for O2, Met/Met (n=19), Val/Met (n=61), and Val/Val (n=44)
subjects.
doi:10.1371/journal.pone.0029283.g001
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(Figure 1E, 1F; SWE: F2,97=0.61, p=0.545; SWA: F2,97=0.58,
p=0.561) EEG derivations. SWE and SWA dissipated across
B2 for the C3 (SWE: F3.36,295.63=38.40, p,0.0001; SWA:
F3.02,265.85=36.51, p,0.0001), Fz (SWE: F2.41,226.56=18.16,
p,0.0001; SWA: F1.92,180.49=11.63, p,0.0001) and O2 channels
(SWE: F1.97,190.58=15.13, p,0.0001; SWA: F1.85,179.55=13.19,
p,0.0001), but not in a differential pattern across genotypes (C3
SWE: F6.72, 295.63=0.93, p=0.480; C3 SWA: F6.04,265.85
=0.76, p=0.603; Fz SWE: F4.82,226.56=0.57, p=0.720; Fz
SWA: F3.84,180.49=0.76, p=0.550; O2 SWE: F3.93,190.58=0.47,
p=0.754; O2 SWA: F3.70,179.55=0.45, p=0.758).
SWE and SWA displayed acute responses to PSD in all
groups—evidenced by percentage increases above the correspond-
ing B2 hour in all channels. SWE% baseline showed a differential
change across PSD for the COMT genotypes in the Fz derivation
(Figure 2C; F4.55,213.81=2.57, p=0.032), but not in Fz SWA%
baseline (Figure 2D; F3.48,165.39=2.11, p=0.092) with Met/Met
subjects showing sharper dissipation of SWE from hour 1 to hour
2 on SR1 and SR5. By contrast, neither SWA% baseline nor
SWE% baseline in the C3 (Figure 2A, 2B; SWA% baseline:
F4.19,201.25=0.86, p=0.490; SWE% baseline: F3.76,180.25=1.25,
p=0.294) or O2 EEG derivations showed significant differential
changes across chronic PSD (Figure 2E, 2F; SWA% baseline:
Figure 2. Slow-wave activity (SWA) and slow-wave energy (SWE) during sleep deprivation for the COMT Val158Met genotypes. Mean
(6SEM) hourly SWA and SWE as a percentage of baseline at the same corresponding hour derived from the C3 (A, B), Fz (C, D) or O2 (E, F) channels on
partial sleep deprivation/restriction night 1 (SR1) and partial sleep deprivation/restriction night 5 (SR5) for hour 1 (H1) and hour 2 (H2) in Met/Met
(open circles), Val/Met (gray triangles) and Val/Val (closed circles) subjects. Met/Met subjects showed differentially greater dissipation during sleep
restriction nights in NREM EEG SWE (derived from the Fz channel)—the putative homeostatic marker of sleep drive—compared with Val/Met and Val/
Val subjects (denoted by
#,p ,0.05). SWA and SWE derived from the Fz and C3 channels increased from SR1 to SR5 (denoted by *, p,0.05). In some
records, EEG signal quality was insufficient or contained too much artifact for reliable power spectral analysis. Thus, the final sample sizes were as
follows: for SR1 and SR5 C3, Met/Met (n=15), Val/Met (n=56) and Val/Val (n=37) subjects; for SR1 and SR5 Fz, Met/Met (n=13), Val/Met (n=54) and
Val/Val (n=36) subjects; for SR1 and SR5 O2, Met/Met (n=14), Val/Met (n=48) and Val/Val (n=36) subjects.
doi:10.1371/journal.pone.0029283.g002
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p=0.574).
SWA% baseline and SWE% baseline derived from Fz increased
across PSD (Figure 2C, 2D; SWA% baseline: F1.74,165.39=3.93,
p=0.027; SWE% baseline: F2.28,213.81=4.08, p=0.014), as did
SWA% baseline derived from C3 (Figure 2B; F2.10,201.25=3.13,
p=0.044), while no other measures were significant (Figure 2A,
2E, 2F; SWE C3% baseline: F1.88,180.25=1.80, p=0.171; SWE
O2% baseline: F2.26,212.28=2.32, p=0.094; SWA O2% baseline:
F2.12,197.47=1.59, p=0.205). In addition, the groups did not differ
in SWE% baseline (F2,96=0.78, p=0.460) or SWA% baseline
(F2,96=1.20, p=0.307) from the C3 (Figure 2A, 2B), Fz
(Figure 2C, 2D; SWE% baseline: F2,94=0.32, p=0.727; SWA%
baseline: F2,95=0.10, p=0.901) or O2 channels (Figure 2E, 2F;
SWE% baseline: F2,94=0.84, p=0.436; SWA% baseline:
F2,93=1.41, p=0.248).
Other EEG Frequencies. Although the primary focus of our
EEG analyses was on the delta frequency in NREM, as the
putative marker of sleep homeostasis, we also examined the other
EEG frequency ranges in NREM and in REM sleep at baseline
and during sleep restriction for the C3, Fz, and O2 derivations.
We failed to find significant genotype differences for any of these
measures (all p’s.0.05).
Polysomnography. Across B2, SR1 and SR5, Val/Val
subjects had more stage 1 sleep (Table 2; duration: F2,99=3.15,
p=0.047; %TST: F2,99=3.72, p=0.028, Bonferroni correction,
p,0.05). At B2, these subjects had shorter REM sleep latency
(F2,113=3.07, p=0.050, Bonferroni correction, p,0.05) and more
stage 1 sleep (duration: F2,113=3.95, p=0.022; %TST:
F2,113=3.30, p=0.040, Bonferroni correction, p,0.05). This
latter difference was maintained at SR1, with Val/Val subjects
showing more stage 1 sleep (duration: F2,113=5.50, p=0.005;
%TST: F2,113=6.16, p=0.003, Bonferroni correction, p,0.05).
The genotypes showed differential PSG responses to PSD
(Table 2). During PSD, Val/Val subjects showed differentially
smaller increases in SWS (%TST: F3.92,194.083=2.81, p=0.027)
and smaller reductions in stage 2 sleep (%TST: F3.87,191.578=2.65,
p=0.036). All genotypes displayed acute responses consistent with
sleep loss and with increases in homeostatic drive: sleep efficiency
and stages 3 and 4 (slow-wave) sleep significantly increased, while
TST, sleep onset latency, WASO, and stages 1 and 2 sleep
significantly decreased (Table 2).
Cognitive Performance and Executive Functioning
Chronic PSD induced significant cognitive performance deficits
across days as demonstrated by increases in PVT lapses (.500ms
reaction times) and in variability for all groups across sleep loss
(Figure 3A). Although all genotypes increased lapses across days
(F2.45,305.67=12.90, p,0.0001), there were no differential respons-
es (F4.89,305.67=0.92, p=0.469) or group differences across days
(F2,125=0.06, p=0.941). Moreover, lapses and other PVT
measures—errors, fastest 10% and median reaction times,
response speed—did not differ across groups during B2 or PSD
(all p’s.0.05).
The groups showed no differential changes in DSST perfor-
mance across PSD (F5.77,360.44=0.50, p=0.802) nor did scores
change across days (F2.88,360.44=1.96, p=0.123) or differ across
groups across days (Figure 3B; F2,125=0.66, p=0.521). There
were no B2 or PSD group differences in DSST performance (all
p’s.0.05). Similarly, there were no differential changes in DS total
performance across PSD (F5.54,346.18=0.67, p=0.660) or group
differences across days (F2,125=0.35, p=0.707) nor did scores
change across days (Figure 3C; F2.77,346.18=0.88, p=0.444).
Moreover, the groups did not show DS performance differences
during B2 or PSD (all p’s.0.05).
The Hayling, Brixton, Controlled Oral Word Association Test,
and Tower of London—executive function tests measured at
SR5—showed no significant differences across the COMT
genotypes (all p’s.0.05).
Subjective Sleepiness and Fatigue
PSD produced increases in KSS sleepiness (Figure 3D;
F3.00,374.85=17.94, p,0.0001) and VAS fatigue scores
(Figure 3E; F2.48,309.02=20.96, p,0.0001) for all genotypes across
days. Despite such increased scores across chronic PSD, there
were no differential responses in these measures (KSS:
F6.00,374.85=1.28, p=0.268; VAS: F4.94,309.02=1.68, p=0.140)
or group differences across days (KSS: F2,125=0.49, p=0.615;
VAS:F2,125=0.15, p=0.858). Similarly, on an unrelated scale, the
Profile of Mood States (POMS), PSD produced increases in
subjective fatigue (POMS-F; Figure 3F; F2.34,292.27=38.01,
p,0.0001) and decreases in vigor (POMS-V; Figure 3G;
F2.35,293.41=8.79, p,0.0001) across days for all genotypes, but
no differential responses (POMS-F: F4.68,292.27=1.43, p=0.217;
POMS-V: F4.70,293.41=0.66, p=0.643) or group differences across
days for either measure (POMS-F: F2,125=2.59, p=0.079;
POMS-V: F2,125=0.46, p=0.632). Moreover, the genotypes did
not differ on KSS, VAS, POMS-F or POMS-V scores during B2
or PSD (all p’s.0.05).
Physiological Sleepiness
Substantiating the subjective sleepiness data, MWT scores did
not differ across groups (F2,86=0.12, p=0.889) or show
differential changes to PSD (F2,86=0.05, p=0.951), although all
genotypes were less able to resist sleep following deprivation
(F1,86=4.88, p=0.030). The groups did not differ on MWT scores
at B2 (F2,86=0.14, p=0.936) or SR5 (F2,86=0.02, p=0.882).
Discussion
The COMT Val158Met polymorphism related to individual
differences in sleep homeostatic responses and physiological sleep
responses to chronic PSD. Met/Met subjects showed differentially
greater declines across days of PSD in NREM EEG SWE—the
putative homeostatic marker of sleep drive—compared with Val/
Met and Val/Val subjects, despite comparable baseline declines.
Val/Val subjects showed differentially smaller SWS increases and
smaller reductions in stage 2 sleep during PSD, had more stage 1
sleep across nights, and a shorter baseline REM sleep latency—all
indicative of a lower homeostatic drive. The genotypes demon-
strated comparable cumulative decreases in cognitive perfor-
mance, and increases in subjective and physiological sleepiness
and fatigue to PSD, with increasing daily inter-subject variability,
and showed no executive function performance differences. The
COMT Val158Met polymorphism may be a genetic marker for
predicting individual differences in sleep homeostasis and
physiology, but not in cognitive and executive function responses,
resulting from sleep loss in a healthy, racially-diverse population of
men and women. Furthermore, these genotype differences in SWE
in response to PSD may extend to psychiatric populations; they
may relate to treatment response in depression and schizophrenia
and may protect against development and exacerbation of
psychosis in these disorders.
Under the phenotypic conditions elicited by PSD, Met/Met
subjects had significantly larger declines in SWE. Moreover,
compared with Val/Val subjects, Met/Met subjects showed
significantly less stage 1 sleep and a longer REM sleep latency at
COMT Predicts Differences in Sleep Physiology
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homeostatic drive. Since such differences were not observed
under basal, fully-rested homeostatic pressure conditions, as was
similarly reported in another study [9], Met/Met subjects may
possess a greater drive, coupled with a more efficient homeostatic
response to sleep loss. Other frequencies, including alpha, which in
prior work has shown COMT genotype differences [8], did not
show genotype-dependent differences in our study. This finding
suggests that the COMT Val158Met polymorphism’s influence is
likely specific to SWA/SWE and is not due to nonspecific effects of
the COMT genotype on EEG-generating mechanisms. Different
genes may modulate basal versus evoked homeostatic responses in
healthy sleepers; therefore, other markers may influence differen-
tial vulnerability in fully-rested conditions.
The COMT polymorphism related to individual differences in
sleep homeostatic and physiological responses to chronic PSD,
contrasting observations in acute TSD [9]. This difference may be
due to the nature of PSD experiments, in which sleep homeostatic
mitigation occurs by partial daily sleep recuperation of sleep
[27,28]. Because of this and other reported differences in
behavioral and physiological responses to chronic PSD and acute
TSD [27,28], it is possible that specific candidate genes play
different roles in the degree of vulnerability and/or resilience to
the neurobehavioral and homeostatic effects of these two
conditions. In further support of this possibility, we recently found
that the PERIOD3 VNTR polymorphism did not relate to
individual differences in neurobehavioral performance responses
to chronic PSD [24], contrasting data from TSD conditions [29].
Future studies should investigate the distinction between PSD and
TSD and the manner in which these conditions relate to
phenotype-genotype interactions.
The Met/Met homeostatic response to sleep loss may possibly
relate to several recent reports of differential responses to
treatment in depression as a function of the COMT Val158Met
genotype. For example, this genotype predicted better antidepres-
sant treatment outcome in major depressive disorder [30–32].
Similarly, Benedetti et al. [33] found that bipolar Met/Met patients
showed better antidepressant response to the combined chron-
otherapeutic treatments of sleep deprivation and bright light
therapy.
Beyond treatment response, we speculate that the faster
dissipation of sleep drive in Met/Met individuals during exposures
to sleep loss may mitigate the development of psychotic features of
psychiatric disorders. For example, the Met/Met genotype has been
related to a reduced risk of experiencing psychotic episodes in
bipolar disorder [34] and has been associated with lower severity
of delusions in schizophrenia [35]. Whether genotype-related
differential responses to sleep loss are important for preventing the
development or exacerbation of clinical symptoms is an important
area of future investigation in adults with psychiatric disorders.
We found that Met/Met individuals had higher IQ scores than
Val/Val individuals, as has been reported previously in the
literature [5,7]. Even after correcting for this IQ difference, we
failed to detect differences across genotypes on a variety of
executive functioning or cognitive tasks, in contrast to other
reports [1-4]. We also failed to detect differences in PVT
performance at baseline or during PSD, in agreement with
findings from a study in TSD [9,10]. Similarly, we found no DS
performance differences across genotypes, in concurrence with
other studies in healthy adults [36,37]. Moreover, a study in TSD
conditions reported no genotype differences in the 2-back test or
the random number generation task [8] and a recent large study in
healthy subjects also failed to find genotype differences [36]. Our
negative results extend meta-analytic results indicating the COMT
Val158Met polymorphism exerts small effects on executive tasks
[7], and support the notion that this polymorphism’s role is not
generalizable to all cognitive tests or to complex cognitive
phenotypes [1,4,37].
Met/Met subjects showed higher sleep homeostatic pressure
during PSD, but not poorer cognitive, executive functioning or
subjective sleepiness responses. Such a separation has been noted
previously whereby the homeostatic sleep responses to chronic
PSD or to TSD have not been reflected in waking neurobehavioral
or cognitive responses [9,10,24,27,38]. We have yet to identify
candidate genes that mediate differential vulnerability to cognitive
changes resulting from PSD.
All genotypes showed greater physiological sleepiness, sleep
homeostasis, and self-rated sleepiness and fatigue, and poorer
cognitive performance across PSD. Thus, PSD produced substan-
tial changes characteristic of cumulative sleep loss, thereby
validating our phenotypic approach [24,27,28,38–40].
Even though we utilized a large sample size compared to all
other candidate gene studies investigating response to sleep loss in
healthy adults [8–10,29,41,42], our findings should be considered
preliminary. They serve as a starting point for future—and
critical—replication in separate populations.
In addition to the need to replicate our findings, our study has a
few limitations. First, we were unable to assess the menstrual cycle
phase of our female participants. Second, it is possible that the
small but significant genotype difference in REM sleep latency at
baseline may affect the relative SWE/SWA values at SR1 and
SR5 [43]. Finally, it is possible that genotype differences in
NREM-REM sleep cycle lengths [44] may be present during
baseline and sleep restriction nights and may influence SWE/
SWA hourly values.
In summary, during chronic partial sleep deprivation, Met/Met
subjects exhibited faster sleep homeostatic dissipation than Val/Val
subjects. The COMT Val158Met polymorphism related to
individual differences in sleep homeostatic, but not executive
functioning and cognitive responses to chronic PSD, suggesting
these measures may be orthogonal and associated with distinct
genetic mechanisms. Thus, the COMT Val158Met polymorphism
may be a biomarker for predicting differential sleep responses
resulting from sleep deprivation in healthy adults and by
extension, in various psychiatric populations. We speculate that
the sharper dissipation of sleep homeostasis in Met/Met individuals
may be protective against the development of psychosis in bipolar
depression and schizophrenia, when exposure to sleep loss occurs,
Figure 3. Neurobehavioral performance during baseline and chronic partial sleep deprivation for the COMT Val158Met groups.
Mean (6SEM) (A) PVT lapses (.500 ms reaction times) per trial, (B) total number correct per trial on the Digit Symbol Substitution Task (DSST) and on
the (C) Digit Span (DS) task, and scores per trial on the (D) Karolinska Sleepiness (KSS), (E) ‘‘Fresh-Tired’’ Visual Analog Scale (VAS), (F) POMS-Fatigue
scale and (G) POMS-vigor scale at baseline (B) and each partial sleep deprivation/restriction night (SR1-SR5) for Met/Met (open circles), Val/Met (gray
triangles) and Val/Val (closed circles) subjects. Although all genotypes showed increased PVT lapses (denoted by *, p,0.0001) and variability across
chronic PSD, there were no differential responses in lapses nor did one genotype show more lapses than the other groups at baseline or during
chronic PSD. There were no group differences or differential changes in DSST or DS scores across chronic PSD nor were there significant changes
across days. For all genotypes, POMS-Vigor scores decreased, and KSS, VAS and POMS-Fatigue scores increased across chronic PSD (denoted by *,
p,0.0001), but there were no differential changes or group differences in these measures during chronic PSD.
doi:10.1371/journal.pone.0029283.g003
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research areas merit further investigation.
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